[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fSFM9LFt81KlXMO7YKTFuZUN5Z-J56Lr7TtI041gcKL4":8,"$fYh6p-SQSQOhx4_HiFTzO-cW7yo8xxEqlz9OCLLBsiNc":55,"$f7Lmgc601Yt1MKHbo4JFre01JmXUmlgHn0f83gfb0iCU":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48686,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"肝恶性肿瘤治疗指南：仑伐替尼、瑞戈非尼与替雷利珠单抗的应用与理解","","https://ystcdn.venuertc.com/venue/AI/14b52978-dc30-4a96-bddf-0d6269505fd2.jpg","\u003Cdiv class=\"custom-drug-guide\">\n  \u003Ch1 id=\"material_title\" class=\"custom-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n    肝恶性肿瘤治疗指南：仑伐替尼、瑞戈非尼与替雷利珠单抗的应用与理解\n  \u003C/h1>\n  \u003Cdiv class=\"custom-intro\">\n    聊到仑伐替尼、瑞戈非尼和替雷利珠单抗，很多正在寻求靶向及免疫药物治疗的患者都不陌生。这三类药品属于分子靶向及免疫调节用药，常用于专业医生指导下施治。用好这些药，效率与安全其实就藏在几个关键细节里。今天带你全面认识7个实用用药要点，让家庭照护和日常管理更加有底。\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image: linear-gradient(to right,#f7fafc,#e6effe 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 剂型和常见规格🔬\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼（Lenvatinib）\u003C/strong>：常见规格为4mg、10mg胶囊。以口服为主。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼（Regorafenib）\u003C/strong>：常用规格为40mg薄膜衣片。片剂需整片吞服。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗（Tislelizumab）\u003C/strong>：为注射剂，推荐只在医疗机构由专业人员静脉滴注给药，单瓶规格通常为100mg/4ml。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">正确做法：每种药品严格按照说明书剂型及规格获取和使用。片剂/胶囊不能嚼碎或掰开，注射剂不可自行注射。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f1f6f8,#f1f6fe 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 药理作用机制简述🧬\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cp>\n        \u003Cstrong>仑伐替尼：\u003C/strong> 主要抑制多种血管生成和肿瘤生长相关酪氨酸激酶受体（如VEGFR、FGFR等），从而阻止新血管生成和细胞增殖，对靶标的作用较为广泛。有助于延缓靶向细胞的异常生长（Matsui et al., 2017）。\n      \u003C/p>\n      \u003Cp>\n        \u003Cstrong>瑞戈非尼：\u003C/strong> 属于多靶点酪氨酸激酶抑制剂，可抑制血管生成因子（VEGFR1-3）、TIE2、PDGFR、FGFR等，阻断信号传导通路，降低细胞活性，干扰多条耐药路径（Bruix et al., 2017）。\u003C/p>\n      \u003Cp>\n        \u003Cstrong>替雷利珠单抗：\u003C/strong> 属程序性细胞死亡蛋白1（PD-1）抑制剂，属于免疫检查点抑制剂，可激活T细胞免疫反应，增强身体针对异常细胞的识别与清除能力（Shen et al., 2020）。\u003C/p>\n      \u003Cdiv class=\"custom-tip\">＊此部分仅供了解原理，无需自己判断机制选择用药。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f6fafd,#f0f6f9 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 用法用量与服药时间⏰\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong> 推荐每日一次，空腹或餐后均可，整粒胶囊吞服，用清水送服。开始剂量需遵医嘱，一般按照体重分层（如≥60kg者首选12mg，<60kg者首选8mg）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong> 建议一次口服，餐后服用效果更佳，可减轻胃肠刺激。通常推荐剂量为每日160mg（即4片），连续服用3周，停1周为一周期；如有不良反应可减量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong> 需由专业医护人员静脉滴注，每3周注射一次，具体用量按照体重或体表面积个体化计算。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">特别提醒：剂量不能随意更改，有疑问务必咨询医生。漏服时不要自行补大剂量。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f7fafc,#f4effe 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 药物相互作用💊\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cp>药品之间的相互作用有时很隐蔽，尤其这三类药都容易受其它药影响。\u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong> 与强效CYP3A4抑制剂/诱导剂合用时可能改变药物血药浓度，需谨慎联合。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong> 避免与强CYP3A4抑制剂和诱导剂（如某些抗生素、抗癫痫药）同服；同时服用PPI类药物（例如奥美拉唑）可能影响药物代谢。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong> 除免疫活性药物外，与绝大多数常规药品相互作用较少，但合用其他靶向或免疫药时需逐项核查兼容性。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">正确做法：将正在服用的所有药物（包括中药/保健品）告知医生，防止不良反应。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f1f6f8,#fffcec 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 特殊人群与剂量调整👵🏻👦🏻\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>老年人：\u003C/strong> 药物代谢略慢，更容易不良反应，建议起始剂量个体化，起始剂量可适当下调，监测副作用。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝功能不全者：\u003C/strong> 三药中仑伐替尼和瑞戈非尼主要经肝脏代谢，肝功能异常时需减量或延长给药间隔。例如仑伐替尼在中重度肝损者推荐起始剂量减半。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肾功能不全者：\u003C/strong> 轻度或中度肾损可按常规剂量，重度肾损时应慎用。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇及哺乳期妇女：\u003C/strong> 三药均未明确安全性，怀孕及哺乳期用药须由专科医生评估决定。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>儿童：\u003C/strong> 此三药在18岁以下应用数据有限，禁止自行给儿童使用。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">每类特殊患者需与医生充分沟通，绝不擅自调整药量。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f6fafd,#ebf5f8 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 不良反应识别与处理方法⚠️\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>仑伐替尼：\u003C/strong> 常见有高血压、乏力、蛋白尿（蛋白尿发生率约13-31%（Kudo et al., 2018））、腹泻、手足皮肤反应。若出现明显不适（如持久高血压或肾功能异常），应及时就医，根据情况减量或停药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>瑞戈非尼：\u003C/strong> 最常见为手足综合征、皮疹、高血压、口腔黏膜炎、腹泻、疲劳等。严重不良反应时需减量或暂停服用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>替雷利珠单抗：\u003C/strong> 免疫相关不良反应包括皮疹、发热、关节痛、免疫系统活性增强导致的肝炎、肺炎等。一旦出现持续发烧、呼吸急促、皮肤大面积异常等，应立刻联系医生。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">遇不良反应时，正确做法是暂停用药、保留药物包装、尽快就医，不可自行增减剂量。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f7fafc,#e6effe 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 储存方法与用药失误处理📦\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贮存环境：\u003C/strong> 这三药均应密封置于25℃以下干燥处，避免受潮与高温。远离儿童与宠物。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>光照问题：\u003C/strong> 药片/胶囊应保留在药盒或原包装中，不用透明瓶明晒。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>有效期/过期：\u003C/strong> 过期药不能使用，请交由药店或医院销毁。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>漏服与过量：\u003C/strong> 忘记服药，应在想起时尽快补服。但距离下一剂时间很近时，略去漏服剂量，按原计划继续。切忌两次联服、一次性吃两倍剂量（FDA, Prescribing Information）。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">药物管理需专人，做好服药记录，避免重复服和误服。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f4effe,#f1f6f8 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 典型用药案例参考📖\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cul>\n        \u003Cli>\n          一位56岁男性在专业医师指导下，先后接受仑伐替尼、瑞戈非尼和替雷利珠单抗联用治疗，期间通过定期随访调整剂量，获得理想控制效果。\u003C/li>\n        \u003Cli>\n          临床中有患者连续服用瑞戈非尼出现轻度手足皮疹，遵医嘱减量后症状好转，疗程持续进行。\u003C/li>\n        \u003Cli>\n          另一患者接受替雷利珠单抗静脉注射，经专科护理后未见严重不良反应，全程安全完成。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"custom-tip\">这些经验说明，遵循规范、密切观察和动态调整是提高用药效果的关键。\u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section\" style=\"background-image:linear-gradient(to right,#f6faf6,#f4effe 60%);\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 重点提醒和结语📝\u003C/h2>\n    \u003Cdiv class=\"custom-content\">\n      \u003Cp>\n        仑伐替尼、瑞戈非尼和替雷利珠单抗各有优势：机制互补、用法灵活、组合潜力高。但每种药物对身体的影响都需要严密关注。\u003Cstrong>最重要的两点：第一，不能随意更改剂量；第二，所有不适、特殊药物、慢性用药必须上报医生核查。\u003C/strong>\n      \u003C/p>\n      \u003Cp>\n        合理管理药品储存、定期复查、记录服药过程，都是安全用药的有力保障。遇到疑问时，专业咨询永远比自行判断更靠谱。\n      \u003C/p>\n      \u003Cp>\n        用好每一片药，让疗效更稳，生活更有质量，这是每个家庭都能做到的最实用守则。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-section custom-ref-section\">\n    \u003Ch2 class=\"custom-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Cul class=\"custom-ref-list\">\n      \u003Cli>\n        Bruix J, Qin S, Merle P, et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. \u003Ci>Lancet\u003C/i>, 389(10064), 56–66.\n      \u003C/li>\n      \u003Cli>\n        Kudo M, Finn RS, Qin S, et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. \u003Ci>Lancet\u003C/i>, 391(10126), 1163–1173.\n      \u003C/li>\n      \u003Cli>\n        Matsui J, Yamamoto Y, Funahashi Y, et al. (2017). Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models and synergizes with anticancer agents. \u003Ci>Proceedings of the American Association for Cancer Research\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Shen L, Guo J, Zhang Q, et al. (2020). Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. \u003Ci>Journal of Hematology & Oncology\u003C/i>, 13(1), 20.\n      \u003C/li>\n      \u003Cli>\n        United States Food and Drug Administration (FDA). (2021). Lenvatinib, Regorafenib, and Tislelizumab Prescribing Information.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.custom-drug-guide * {\n  box-sizing: border-box;\n}\n.custom-drug-guide {\n  max-width: 800px;\n  margin: 30px auto;\n  font-family: 'Segoe UI', Arial, 'Microsoft Yahei', sans-serif;\n  background: #fafbfc;\n  padding: 24px 26px 40px 26px;\n  border-radius: 18px;\n  box-shadow: 0 3px 16px 0 rgba(134,156,211,0.10);\n}\n.custom-title {\n  font-size: 2.3em;\n  font-weight: 700;\n  color: #394e75;\n  margin-bottom: 20px;\n  text-align: center;\n  letter-spacing: 1px;\n}\n.custom-intro {\n  background: #f2f8fd;\n  font-size: 1.15em;\n  color: #505b73;\n  margin-bottom: 23px;\n  padding: 16px 22px;\n  border-radius: 10px;\n  line-height: 1.78em;\n  box-shadow: 0 1px 5px 0 rgba(174,188,211,0.06);\n}\n.custom-section {\n  margin-top: 28px;\n  padding: 29px 20px 24px 27px;\n  border-radius: 15px;\n  box-shadow: 0 2px 10px 2px rgba(184,202,240,0.09);\n  background-size: cover;\n}\n.custom-h2 {\n  font-size: 1.28em;\n  font-weight: 600;\n  color: #3056a3;\n  margin-bottom: 15px;\n  padding-bottom: 3px;\n  letter-spacing: 0.5px;\n  display: flex;\n  align-items: center;\n}\n.custom-content>ul,.custom-content>ol {\n  margin-left: 1.3em;\n  margin-bottom: 0.2em;\n}\n.custom-content>ul>li {\n  margin-bottom: 9px;\n  font-size: 1.05em;\n  line-height: 1.8em;\n  color: #46536c;\n}\n.custom-content p {\n  font-size: 1.06em;\n  line-height: 1.82em;\n  color: #4d5872;\n  margin-bottom: 11px;\n}\n.custom-tip {\n  background: linear-gradient(90deg,#e9eefc 75%,#f8fafc 100%);\n  padding: 9px 18px;\n  border-left: 4px solid #a7b8ef;\n  border-radius: 6px;\n  font-size: 1em;\n  color: #5976b6;\n  margin-top: 14px;\n  margin-bottom: 3px;\n}\n.custom-ref-section {\n  background: #f4f7fd;\n  margin-top: 34px;\n  padding: 26px 18px 16px 22px;\n}\n.custom-ref-list {\n  margin-left: 1.1em;\n}\n.custom-ref-list li {\n  margin-bottom: 8px;\n  color: #546392;\n  font-size: 0.99em;\n}\n@media (max-width: 900px) {\n  .custom-drug-guide {\n    padding: 14px 4% 25px 4%;\n  }\n}\n@media (max-width: 650px) {\n  .custom-title {font-size:1.25em;}\n  .custom-section,\n  .custom-ref-section {padding: 13px 7px 16px 13px;margin-top:18px;}\n  .custom-intro { font-size: 0.98em; padding: 10px 6px;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"custom-drug-guide\">\n  \u003Ch1 id=\"material_title\" class=\"custom-title\" style=\"color: rgb(44,",570,"2025-07-14 13:47:30","肝恶性肿瘤, 仑伐替尼, 瑞戈非尼, 替雷利珠单抗, 用药指南, 药物相互作用, 不良反应, 药物管理","全面了解仑伐替尼、瑞戈非尼和替雷利珠单抗这三种靶向药物的应用，掌握用药要点与安全性管理，提高治疗效果与生活质量。","2025-07-20 16:22:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]